IL155029A0 - Treatment of gastrointestinal stromal tumors - Google Patents

Treatment of gastrointestinal stromal tumors

Info

Publication number
IL155029A0
IL155029A0 IL15502901A IL15502901A IL155029A0 IL 155029 A0 IL155029 A0 IL 155029A0 IL 15502901 A IL15502901 A IL 15502901A IL 15502901 A IL15502901 A IL 15502901A IL 155029 A0 IL155029 A0 IL 155029A0
Authority
IL
Israel
Prior art keywords
treatment
gastrointestinal stromal
stromal tumors
methylpiperazin
ylamino
Prior art date
Application number
IL15502901A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL155029(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL155029A0 publication Critical patent/IL155029A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
IL15502901A 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors IL155029A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
PCT/EP2001/012442 WO2002034727A2 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Publications (1)

Publication Number Publication Date
IL155029A0 true IL155029A0 (en) 2003-10-31

Family

ID=22920224

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15502901A IL155029A0 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors
IL155029A IL155029A (en) 2000-10-27 2003-03-20 Use of 4 - (4 - methylphyprazine - 1 - il - methyl) - N - [4 - methyl - 3 - (4 - pyridine - 3 - il) pyrimidine - 2 - il - amino) phenyl] - benzamide for the preparation of a drug for treatment In cancer of the gastrointestinal tract

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155029A IL155029A (en) 2000-10-27 2003-03-20 Use of 4 - (4 - methylphyprazine - 1 - il - methyl) - N - [4 - methyl - 3 - (4 - pyridine - 3 - il) pyrimidine - 2 - il - amino) phenyl] - benzamide for the preparation of a drug for treatment In cancer of the gastrointestinal tract

Country Status (26)

Country Link
US (1) US6958335B2 (ru)
EP (1) EP1332137B1 (ru)
JP (1) JP4386635B2 (ru)
KR (1) KR100885129B1 (ru)
CN (1) CN1276754C (ru)
AT (1) ATE321556T1 (ru)
AU (2) AU1826202A (ru)
BR (1) BRPI0114870B8 (ru)
CA (1) CA2424470C (ru)
CY (1) CY1105055T1 (ru)
CZ (1) CZ303944B6 (ru)
DE (1) DE60118430T2 (ru)
DK (1) DK1332137T3 (ru)
ES (1) ES2260317T3 (ru)
HK (1) HK1058193A1 (ru)
HU (1) HU229106B1 (ru)
IL (2) IL155029A0 (ru)
MX (1) MXPA03003703A (ru)
NO (1) NO324948B1 (ru)
NZ (1) NZ525254A (ru)
PL (1) PL209733B1 (ru)
PT (1) PT1332137E (ru)
RU (1) RU2301066C2 (ru)
SK (1) SK287335B6 (ru)
WO (1) WO2002034727A2 (ru)
ZA (1) ZA200302155B (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1700917B (zh) * 2001-05-16 2010-04-28 诺瓦提斯公司 含n-(5-{4-[4-甲基-(1-哌嗪基)甲基]-苯甲酰氨基}-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶-胺和化疗药的联合形式
US7700610B2 (en) * 2001-06-29 2010-04-20 Ab Science Use of tyrosine kinase inhibitors for treating allergic diseases
ES2274075T3 (es) * 2001-06-29 2007-05-16 Ab Science Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
EP1401412A2 (en) * 2001-06-29 2004-03-31 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
DE60212627T2 (de) * 2001-06-29 2007-06-14 Ab Science Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung von entzündlichen Krankheiten
US7727731B2 (en) * 2001-06-29 2010-06-01 Ab Science Potent, selective and non toxic c-kit inhibitors
EP1427379B1 (en) * 2001-09-20 2008-08-13 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
WO2003035050A2 (en) * 2001-09-20 2003-05-01 Ab Science Use of tyrosine kinase inhibitors for promoting hair growth
DK1478380T3 (da) * 2002-02-27 2006-11-27 Ab Science Anvendelse af tyrosinkinase-inhibitorer til behandling af CNS-lidelser
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
DE602004030265D1 (de) * 2003-09-19 2011-01-05 Novartis Ag Behandlung von gastrointestinalen stromatumoren mit imatinib und midostaurin
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
EP2061468A4 (en) * 2006-09-11 2011-05-04 Curis Inc TYROSINE KINASE INHIBITORS CONTAINING ZINC BINDING CHARACTERISTIC GROUP
WO2008033747A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
SG193291A1 (en) 2011-03-04 2013-10-30 Newgen Therapeutics Inc Alkyne substituted quinazoline compound and methods of use
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP6464084B2 (ja) 2012-07-27 2019-02-06 イズミ テクノロジー，エルエルシー 排出阻害剤およびこれを用いる治療法
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
WO2019016673A2 (en) 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
CN118557737A (zh) 2018-01-31 2024-08-30 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
ES2966336T3 (es) 2019-12-30 2024-04-22 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de cinasa amorfos y métodos de uso de las mismas
JP7534416B2 (ja) 2019-12-30 2024-08-14 デシフェラ・ファーマシューティカルズ，エルエルシー １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (ru) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CA2342222A1 (en) * 1998-08-31 2000-03-09 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

Also Published As

Publication number Publication date
DE60118430T2 (de) 2006-10-26
NO324948B1 (no) 2008-01-07
SK287335B6 (sk) 2010-07-07
CZ303944B6 (cs) 2013-07-10
EP1332137B1 (en) 2006-03-29
NO20031833L (no) 2003-04-24
CN1276754C (zh) 2006-09-27
RU2301066C2 (ru) 2007-06-20
HUP0301512A2 (hu) 2003-11-28
CA2424470C (en) 2009-06-09
BRPI0114870B8 (pt) 2021-05-25
MXPA03003703A (es) 2005-01-25
PL209733B1 (pl) 2011-10-31
US20040023976A1 (en) 2004-02-05
NZ525254A (en) 2006-02-24
WO2002034727A2 (en) 2002-05-02
HU229106B1 (en) 2013-07-29
ZA200302155B (en) 2004-04-22
AU2002218262B2 (en) 2005-09-29
DK1332137T3 (da) 2006-07-17
IL155029A (en) 2009-09-22
HK1058193A1 (en) 2004-05-07
ATE321556T1 (de) 2006-04-15
CN1622808A (zh) 2005-06-01
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
KR20030051656A (ko) 2003-06-25
CA2424470A1 (en) 2002-05-02
CZ20031152A3 (en) 2004-04-14
EP1332137A2 (en) 2003-08-06
BRPI0114870B1 (pt) 2020-06-16
PT1332137E (pt) 2006-07-31
US6958335B2 (en) 2005-10-25
AU1826202A (en) 2002-05-06
SK5182003A3 (en) 2004-02-03
CY1105055T1 (el) 2010-03-03
JP2004512328A (ja) 2004-04-22
ES2260317T3 (es) 2006-11-01
BR0114870A (pt) 2004-02-17
DE60118430D1 (de) 2006-05-18
PL362148A1 (en) 2004-10-18
JP4386635B2 (ja) 2009-12-16
KR100885129B1 (ko) 2009-02-23

Similar Documents

Publication Publication Date Title
AU1826202A (en) Treatment of gastrointestinal stromal tumors
HK1028599A1 (en) Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
IL164678A (en) High-drug tablet containing 4– (4-methylpiprazine – 1-ylamethyl) -n - [(4-methyl-3– (4-pyridin-3-il) pyrimidine-2-ylamino) phenyl] -benzamide or compatible salt Its pharmaceutical and process for its preparation
HK1072192A1 (en) Treatment of rheumatoid arthritis using imatinib
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
BR0316126A (pt) Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica
AU2003216621A1 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
BR0312242A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil]-benzamida para o tratamento da fibrose pulmonar
WO2004103374A3 (en) Imatinib combinations for head and neck cancers
AU2003209521A1 (en) Use of 4-(4-methylpiperazin-1-ylmethyl)-n(4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl)-benzamide for treating seminomas
NZ610401A (en) Inhibitors of the mutant form of kit